| (Values in U.S. Thousands) | Jun, 2025 | Jun, 2025 | Jun, 2025 | Apr, 2026 | Apr, 2026 |
| Sales | 3,633 | 299 | 292 | 9 | 0 |
| Sales Growth | +1,114.27% | +2.35% | +3,210.60% | unch | unch |
| Net Income | -38,342 | -47,949 | -34,611 | -30,339 | 0 |
| Net Income Growth | +20.04% | -38.54% | -14.08% | unch | unch |
Radiopharm Theranostics Ltd (RAD.AX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.
Fiscal Year End Date: 06/30